Condition: Toxoplasmosis, Cerebral · Sponsor: Universitas Padjadjaran
Toxoplasma gondii infects over one third of the global human population. Cerebral toxoplasmosis is the most common opportunistic infection in HIV patients resulting in up to 50% of mortality with proper treatment and 80% without it. The fatality mainly due to the brain edema resulted from the mass effect lesion. In addition of anti toxoplasmosis given, adjunctive therapy such as steroid is recommended in order to reduce brain edema, but the dose and duration of administration in cerebral toxoplasmosis has not been evaluated in a clinical trial. Adjunctive therapy given in cerebral toxoplasmosis patients still remains unclear. Moreover, its safety in immunodeficiency cases is still debatable.
This description comes directly from the study's public registry record.
Ahmad R Ganiem, M.D., PhD · +62 878 2288 3773 · rizalbdg@gmail.com
Sofiati Dian, M.D., PhD · +62 812 2119 519 · sofiatidian@gmail.com
Always discuss trial participation with your own doctor first.
| Hasan Sadikin General Hospital | Bandung, West Java, Indonesia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04341155